Which are the causes of Cardiofaciocutaneous / Cfc Syndrome?

Cardiofaciocutaneous (CFC) syndrome is a rare genetic disorder caused by mutations in genes that regulate the RAS/MAPK signaling pathway, which is essential for normal cell growth and development. These mutations occur sporadically, meaning they are typically not inherited from parents but arise as new changes in the individual's genetic code.

What genetic mutations cause Cardiofaciocutaneous syndrome?

Cardiofaciocutaneous syndrome is classified as a "RASopathy" because it is caused by mutations in specific genes within the RAS/MAPK pathway. Research indicates that approximately 75% to 80% of individuals with Cardiofaciocutaneous syndrome have a mutation in one of the following genes:

• BRAF: The most common cause, accounting for about 75% of cases.


• MAP2K1 and MAP2K2: Responsible for approximately 25% of cases.


• KRAS: A rare cause of Cardiofaciocutaneous syndrome, identified in a small percentage of patients.

Are there environmental or external triggers for CFC syndrome?

There are no known environmental, dietary, or infectious triggers for Cardiofaciocutaneous syndrome. Because the condition is rooted in a fundamental genetic mutation present from conception, it cannot be caused or prevented by external factors. Unlike risk factors for common diseases (such as diet or lifestyle), the "cause" of Cardiofaciocutaneous syndrome is strictly biological and internal.

Is Cardiofaciocutaneous syndrome inherited?

In almost every documented case, Cardiofaciocutaneous syndrome occurs as a de novo (new) mutation. This means the genetic change is not inherited from the parents; rather, it occurs spontaneously in the egg or sperm cell or shortly after fertilization. Consequently, the recurrence risk for siblings of an affected child is generally very low, though consultation with a clinical geneticist is recommended for personalized family planning.

What is current research revealing about the etiology?

Current research focuses on understanding how different mutations in the RAS/MAPK pathway lead to the specific range of symptoms seen in Cardiofaciocutaneous syndrome. Scientists are using cellular models to determine how these mutations disrupt communication between cells, which may eventually lead to targeted therapeutic interventions that address the underlying molecular dysfunction.

Next steps

• Consult with a clinical geneticist to confirm the diagnosis via molecular genetic testing.


• Connect with the 36 members of the DiseaseMaps.org community to share experiences and coping strategies.


• Coordinate care through a multidisciplinary team, including cardiologists, dermatologists, and developmental pediatricians.

Medical disclaimer: This information is for educational purposes only and does not constitute medical advice; please consult a healthcare professional for diagnosis and treatment.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Cardiofaciocutaneous syndrome.


• Orphanet: Cardiofaciocutaneous syndrome (ORPHA:149).


• OMIM (Online Mendelian Inheritance in Man): Entry #115150.


• CFC International: Resources and research updates for families.